The well accomplished Professional life of Dr Scott Rocklage

Scott Rocklage, Ph.D. started his career at Berkley University in California with a B.S. in chemistry. He then went on MIT, Massachusetts Institute of Technology and earned his Ph.D. in the lab of 2005 Nobel Prize winner Dr. Richard Schrock. He considers it lucky and a great honor to have been able to work with Dr. Schrock. Since then he has become a leading figure in healthcare management. Read more: Idea Mensch | Scott Rocklage

He currently is a managing partner at 5AM Ventures. He came to them in 2004 as a Venture Partner in 2003 and became a managing partner in 2004. Dr. Rocklage was well prepared for this role because of his twenty years plus working in healthcare management.

Examples of his leadership capabilities allowed Dr. Rocklage and his team to have the approval of a few drug applications in the US. They include Cubicin, Teslascan, and Omniscan. He also holds over twenty US patents and has had six drug candidates enter into clinical drug trials.

Dr. Rocklage not only is a managing partner at 5Am Ventures but sits and has sat on the board of several other companies. He once served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, President, CEO and Chairman of Nycomed Interventional and has also held various R&D positions at Salutar and Catalytica.

He also was formerly the Executive Chairman of Ilypsa (acquired by Amgen) and Miikana (acquired by EntreMed). Currently, he serves as Board Chairman of Achaogen, Relypsa and Semprus as well as on the Boards of WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute. Learn more about Scott Rocklage: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY

Not only is he a man of science and management he’s a philanthropist. When approached by his alma mater MIT about donating he responded with sure where are you in the most need? He and his wife Patty were honored last year with their major gift that assisted with the costs associated with the renovation of Lester Wolfe Professor of Chemistry, Moungi Bawendi’s nanochemistry and nanotechnology lab space in Building 2.

Read more: Scott Racklage | Bloomberg